In the high-stakes world of biotechnology, where years of research and millions of dollars can hinge on a single hypothesis, the ability to change course when evidence demands it is not a sign of failure but a mark of strong leadership. That is the message from Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer at BE Therapeutics, who has spent more than three decades navigating the intersection of academic research, biotech entrepreneurship, and R&D leadership.
Ashton-Rickardt's career has included professorships at the University of Chicago and Imperial College London, founding Smith Therapeutics, serving as Chief Scientific Officer at Sigilon Therapeutics, advising companies through Flagship Pioneering, and helping build Halyard Therapeutics and BE Therapeutics. Across these roles, he has observed how easily commitment to an idea can morph into attachment to it, clouding judgment and slowing progress.
"You have to separate attachment to the idea from attachment to the problem," Ashton-Rickardt said. "If the problem is important, there may be several ways to approach it." This distinction is particularly critical in biotechnology, where scientific programs often evolve as new data emerge. A hypothesis that looked promising at the start may need to be adjusted, narrowed, or even abandoned entirely.
For Ashton-Rickardt, changing direction does not automatically mean an earlier idea failed. In many cases, it signals that the team has learned enough to make a better decision. "Flexibility is important because changing your approach is not necessarily an admission that you failed," he said. "Sometimes it is evidence that you learned something." This perspective challenges the stigma often associated with pivoting in scientific research, where stubborn persistence can be mistaken for conviction.
One of the more difficult aspects of scientific leadership, Ashton-Rickardt believes, is providing direction without creating false certainty. Researchers, executives, investors, and teams often need decisions before every question has been answered, creating pressure on leaders to sound more certain than the evidence justifies. He advocates for transparency about what is known, what remains uncertain, and what would cause a decision to change.
"There is a difference between providing direction and pretending to know the future," Ashton-Rickardt said. "In biotech, there are simply too many unknowns." Rather than weakening confidence, this kind of transparency can strengthen it. When teams understand that new information is expected to influence decisions, they may be more willing to raise concerns, question assumptions, and share evidence that challenges the current plan.
Ashton-Rickardt's views have been shaped by a career that repeatedly required him to enter unfamiliar territory. Raised in a working-class family in the UK, he worked his way through university and into academic science before leaving a long-established academic career to return to Boston and start a biotech company. That transition demanded he learn a new operating environment while drawing on years of scientific experience. He has since moved between startups, established biotech companies, research organizations, and investment-backed environments. Throughout those changes, he says curiosity has remained one of the most important qualities a leader can keep.
"The people I enjoy working with tend to ask good questions, even when those questions make the project more complicated," Ashton-Rickardt said. He also believes leaders should be willing to admit what they do not know. In his experience, someone who has thought deeply about an idea does not need to pretend it has no weaknesses. Instead, strong scientific thinking often shows up in the ability to explain what evidence would change a person's mind.
Ashton-Rickardt's current work remains focused on engineered cell therapies and approaches to treating neurological and other serious diseases. At BE Therapeutics, where he serves as Managing Director and Chief Scientific Officer, and at Halyard Therapeutics, where he is a co-founder and Chief Scientific Officer, his work continues to center on translating complex scientific ideas into programs that can move forward. That process, he says, requires conviction, but conviction has to remain connected to evidence.
"The goal is not to prove that your first idea was right," Ashton-Rickardt said. "The goal is to solve an important problem." For scientists and biotech leaders, that difference can shape everything from how teams run experiments to how companies decide where to invest time and resources. It can also make scientific organizations more adaptable at a time when new tools, new data, and new therapeutic approaches continue to change what is possible.
